McKesson AI Stock Analysis
Want to see MCK full AI Analyst Report?
McKesson (MCK) AI Stock Analysis
McKesson
(NYSE:MCK)
The score is primarily supported by strong cash-flow generation and a very positive, guidance-raising earnings outlook. Offsetting factors are elevated balance-sheet risk (negative equity and rising debt) and a less attractive valuation (higher P/E with a low dividend yield), while technicals remain strong but somewhat overextended (high RSI).
McKesson Key Performance Indicators (KPIs)
Revenue by SegmentShows how revenue is distributed across various business segments, indicating which areas are growing or declining and where the company is focusing its efforts.
McKesson’s revenue mix is shifting: U.S. Pharmaceuticals remain the revenue backbone, but Oncology & Multispecialty has quickly become a material, higher‑margin growth engine via acquisitions, driving outsized operating‑profit gains and the upbeat oncology guidance. The sharp drop in International reflects the Norway divestiture and reclassification. Prescription Technology Solutions is steady; Medical‑Surgical is stable but earmarked for separation, which will free capital while adding near‑term financing and expense noise. Expect GLP‑1 and branded‑pricing volatility to create quarter‑to‑quarter forecast swings despite improving underlying margins.
McKesson (MCK) vs. SPDR S&P 500 ETF (SPY)
- Market Cap
- $127.58B
- Dividend Yield
- 0.31%
- Average Volume (3M)
- 800.59K
- Price to Earnings (P/E)
- 28.4
- Beta (1Y)
- -0.10
- Revenue Growth
- 8.19%
- EPS Growth
- 21.01%
- Country
- US
- Employees
- 42,300
- Sector
- Healthcare
- Sector Strength
- 51
- Industry
- Medical - Distribution
McKesson Business Overview & Revenue Model
Company Description
McKesson Corporation is a prominent global provider of healthcare services, operating extensively in both the United States and international markets. Its diverse operations are strategically organized into four key business segments. The U.S. Pharma...
How the Company Makes Money
McKesson makes money primarily by distributing pharmaceuticals and healthcare products and charging customers for the value it provides in procurement, inventory management, logistics, and related services. 1) Pharmaceutical distribution (core revenu...
McKesson Earnings Call Summary
The call was strongly positive. McKesson reported broad-based revenue, operating profit, and adjusted EPS growth; raised fiscal 2027 guidance; highlighted strong cash generation, liquidity, shareholder returns, and strategic expansion in oncology, biopharma services, specialty care, and home-based infusion. The principal challenges were the medical-surgical operating profit decline and muted outlook, branded pharmaceutical pricing and generic conversions, higher interest expense, normalized prior authorization volumes, and uncertainty around 340B policy. These lowlights were outweighed by the company's reported performance, raised outlook, and strategic momentum.
Q2-2027 Updates
Positive Updates
Negative Updates
Company Guidance
For fiscal 27, McKesson raised adjusted earnings per diluted share guidance to $45.60 to $46.40, implying adjusted EPS growth of 17% to 19%, or 19% to 21% excluding the impact of the Norway divestiture and the net gains within the U.S. Oncology Network in fiscal 2026, versus a long term growth target of 13% to 16%; revenue growth is anticipated at 6% to 10% and operating profit growth at 12% to 16%. North American pharmaceutical revenue growth is anticipated at 5% to 9% and operating profit growth at 14% to 18%; oncology and multispecialty revenue growth at 20% to 24% and operating profit growth at 18% to 22%, or 22% to 26% excluding the net gains of $51 million in fiscal 2026; prescription technology solutions revenue growth at 2.5% to 6.5% and operating profit growth at 11% to 15%; and MedSurg revenue growth at 1% to 6% with operating profit to range from a 4% decline to flat. Corporate expenses are anticipated at the high end of the $580 million to $640 million range, interest expense at the high end of $380 million to $420 million, income attributable to noncontrolling interest at $290 million to $320 million, and the full year effective tax rate at 18% to 19%; free cash flow is anticipated at approximately $4.5 billion to $4.9 billion, approximately $5 billion of shares are expected to be repurchased during fiscal 27, and diluted weighted average shares outstanding are estimated to be in the range of 115.5 million to 117.5 million.
McKesson Financial Statement Overview
Summary
Strong and improving cash generation (TTM operating cash flow $7.5B; free cash flow $6.9B, ~94% of net income) and large-scale revenue growth support the score. The key offset is balance-sheet risk: persistent negative equity (TTM -$4.0B) and higher debt ($11.2B TTM) reduce financial flexibility despite steady (but thin) distributor margins.
Income Statement
74PositiveBalance Sheet
38NegativeCash Flow
82Very Positive| Breakdown | TTM | Mar 2026 | Mar 2025 | Mar 2024 | Mar 2023 | Mar 2022 |
|---|---|---|---|---|---|---|
Income Statement | ||||||
| Total Revenue | 418.79B | 403.43B | 359.05B | 308.95B | 276.71B | 263.97B |
| Gross Profit | 15.37B | 14.55B | 12.48B | 12.20B | 11.87B | 12.65B |
| EBITDA | 7.55B | 7.18B | 5.25B | 4.67B | 5.49B | 2.87B |
| Net Income | 4.70B | 4.76B | 3.29B | 3.00B | 3.56B | 1.11B |
Balance Sheet | ||||||
| Total Assets | 92.32B | 82.32B | 75.14B | 67.44B | 62.32B | 63.30B |
| Cash, Cash Equivalents and Short-Term Investments | 6.53B | 3.98B | 5.69B | 4.58B | 4.68B | 3.53B |
| Total Debt | 11.16B | 8.61B | 7.39B | 7.39B | 7.29B | 7.54B |
| Total Liabilities | 95.90B | 83.16B | 76.83B | 69.04B | 63.81B | 65.09B |
| Stockholders Equity | -3.95B | -2.17B | -2.07B | -1.97B | -1.86B | -2.27B |
Cash Flow | ||||||
| Free Cash Flow | 6.91B | 5.41B | 5.23B | 3.63B | 4.60B | 3.90B |
| Operating Cash Flow | 7.50B | 6.16B | 6.08B | 4.31B | 5.16B | 4.43B |
| Investing Cash Flow | -188.00M | -3.43B | -733.00M | -1.07B | -542.00M | -89.00M |
| Financing Cash Flow | -4.79B | -4.63B | -3.96B | -3.34B | -4.37B | -6.32B |
McKesson Technical Analysis
Price Trends
Market Momentum
Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For MCK, the sentiment is Positive. The current price of 1105.04 is above the 20-day moving average (MA) of 1033.08, above the 50-day MA of 959.03, and above the 200-day MA of 874.50, indicating a bullish trend. The MACD of 39.25 indicates Negative momentum. The RSI at 75.24 is Negative, neither overbought nor oversold. The STOCH value of 80.03 is Negative, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Positive sentiment for MCK.
McKesson Risk Analysis
McKesson disclosed 38 risk factors in its most recent earnings report. McKesson reported the most risks in the "Production" category.
Latest Risks Added
1 New RiskMcKesson Peers Comparison
Overall Rating
GRDN74Outperform
CAH73Outperform
PBH68Neutral
MCK68Neutral
HSIC65Neutral
COR64Neutral
Financial Indicators
| Name | Overall Rating | Market Cap | P/E Ratio | ROE | Dividend Yield | Revenue Growth | EPS Growth |
|---|---|---|---|---|---|---|---|
| 74Outperform | $3.13B | 41.87 | 31.83% | ― | 4.85% | 83.17% | |
| 73Outperform | $65.61B | 36.58 | -62.56% | 0.72% | 10.00% | 16.74% | |
| 68Neutral | $2.28B | 14.65 | 8.19% | ― | 5.10% | -19.73% | |
| 68Neutral | $127.58B | 28.38 | -161.18% | 0.31% | 8.19% | 21.01% | |
| 65Neutral | $9.39B | 22.88 | 13.13% | ― | 6.15% | 15.68% | |
| 64Neutral | $68.11B | 19.88 | 115.76% | 0.69% | 5.00% | 124.34% | |
| Sector * | 51Neutral | $7.86B | -0.30 | -43.30% | 2.27% | 22.53% | -2.21% |
* Healthcare Sector Average
Performance Comparison
| Show on chart | Ticker | Company Name | Price | Change | % Change |
|---|---|---|---|---|---|
| MCK | McKesson Corporation | 1105.04 | 255.91 | 30.14% | |
| COR | Cencora, Inc. | 356.94 | -0.97 | -0.27% | |
| CAH | Cardinal Health | 283.85 | 78.27 | 38.07% | |
| HSIC | Henry Schein | 84.96 | 14.36 | 20.34% | |
| PBH | Prestige Consumer Healthcare | 48.00 | -10.49 | -17.93% | |
| GRDN | Guardian Pharmacy Services, Inc. Class A | 49.43 | 21.88 | 79.42% |
McKesson Corporate Events
McKesson, CD&R to Acquire Option Care Health
PositiveOn October 6, 2026, Clayton, Dubilier & Rice and McKesson agreed to acquire Option Care Health, the largest independent U.S. provider of home and alternate site infusion services, for $32.05 per share in a deal valuing the company at about $5.8 billi...
McKesson Reports Recent Cybersecurity Incident Under Regulation FD
NegativeMcKesson Corporation reported that on August 25, 2026, it discovered a cybersecurity incident affecting its information systems, and an investigation into the breach remains in its early stages. As of the date of the filing, the company has not concl...
Disclaimer
This AI Analyst Stock Report is automatically generated by our AI systems using advanced algorithms and publicly available financial, technical, and market data. While the information provided aims to be accurate and insightful, it is intended for informational purposes only and should not be considered financial advice. Any content created by an AI (Artificial Intelligence) system may contain inaccuracies and/or contain errors. Investing in stocks carries inherent risks, and past performance is not indicative of future results. This report does not account for your personal financial circumstances, objectives, or risk tolerance. Always conduct your own research or consult with a qualified financial advisor before making investment decisions. The analysis and recommendations provided are based on historical and current data and may not fully reflect future market conditions or unexpected developments. Neither the creators of this report nor its affiliated entities guarantee the accuracy, completeness, or reliability of the information presented. Use this report at your own discretion and risk.
Date of analysis: Nov 05, 2026
